CAC
BMY.RT

Certified Advisory Corp’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Certified Advisory Corp’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$0 Buy
+100
New +$361 ﹤0.01% 832

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Certified Advisory Corp's BMY.RT Position: Q2 2020 in Review

Certified Advisory Corp opened a new position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q2 2020: 100 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #832 among its holdings.

583 funds tracked by Wall St. Rank hold BMY.RT as of Q2 2020.

  • Certified Advisory Corp held 100 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $0 as of Q2 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights was a new Certified Advisory Corp position in Q2 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of Certified Advisory Corp's portfolio in Q2 2020, its #832 holding.
  • 583 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q2 2020.

Based on Certified Advisory Corp's 13F filing for Q2 2020, filed 27 Jul 2020.